Oral Tranexamic Acid After Total Knee Arthroplasty

Launched by RUSH UNIVERSITY MEDICAL CENTER · Mar 18, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how effective a medication called oral tranexamic acid (TXA) is for patients who have undergone total knee arthroplasty (TKA), which is a surgery to replace the knee joint. The study will compare patients who take TXA for either 3 or 7 days after their surgery with those who do not take the medication. Researchers want to find out if TXA helps reduce pain and improve how well patients can move their knee in the first few months after surgery, while also checking if there is any difference in blood loss and the need for blood transfusions.

To be eligible for this trial, participants must be adults aged 65 to 74 who are scheduled for a total knee replacement at a specific hospital. They should be willing to take a chance on whether they receive the medication or not and answer daily questions about their pain levels and how well they are getting around. However, certain individuals, such as those with a recent history of blood clots, heart attacks, strokes, or those taking specific medications, may not qualify. Participants can expect to be part of a study that aims to improve pain management and recovery outcomes for future knee surgery patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Any patient undergoing primary TKA at Rush main hospital or participating ASC
• • Willingness to undergo randomization to take medication potentially up to 7 days post op.
• • Willing to answer daily questions on pain, functionality and opioid consumption
• Exclusion Criteria:
• • History of venous thromboembolism, MI, or stroke in the past year
• • Patients on any chronic anticoagulation medications besides Aspirin
• • Patients with Cancer
• • Patients with end stage renal disease that are on dialysis
• • Drug allergy to TXA
• • Taking oral birth control
• • Unable to provide consent